Denosumab for giant cell tumour of bone: success and limitations
Mené dans 12 pays sur 532 patients atteints d'une tumeur osseuse à cellules géantes, cet essai de phase II évalue l'efficacité, du point de vue du délai avant progression ou récidive de la maladie, et la toxicité du dénosumab
Intralesional surgery, with or without local adjuvant, or en-bloc resection is the treatment of choice for giant-cell tumor of bone. However, recurrence rates remain high (10–50%), and surgery for tumour in common locations such as the pelvis and spine have unacceptably high morbidity. Improved targeted therapy for local and systemic control is needed. The eponymously named multinucleated giant cells are reactive and not neoplastic. The true neoplastic cells are bone forming mesenchymal stem-like cells that induce and drive the giant cells by mechanisms under study. Nevertheless, new therapies have focused on disrupting the reactive giant cells and their communication with the neoplastic mesenchymal cells.
The Lancet Oncology , commentaire, 2018